Rezultati pretraživanja
  1. prije 6 sati

    FIND OUT WHY THIS DISRUPTIVE TECH IS ALREADY INTEGRATED AND BEING FURTHER INTEGRATED WITH and many other big tech companies

  2. 3. velj

    Analysts Set Audentes Therapeutics Inc Target Price at $55.44

  3. 3. velj

    THE RISE OF THE PHOENIX BABY---COMING OFF 5 YEAR LOWS 💫O/S=25m 💫PATENT PENDING TECH THAT RIVALS AND HUGE BIG TECH INTEGRATIONS 💫OVER 937,000 MEMBERS WITH RECURRING REVENUE AND BACKLOG

  4. 1. velj

    In this environment with , next US elections, how do you expect stocks to move in Q1 2020

  5. 31. sij

    : ARE YOU READY TO MISS THE NEXT , , , OR ? 💫THIS IS A INDUSTRY DISRUPTOR WORTH LOOKING INTO AND AT 5 YEAR LOWS

  6. 31. sij

    Audentes Therapeutics Inc Receives Average Rating of “Hold” from Analysts

  7. 30. sij
  8. 29. sij

    in Uptrend: Stochastic indicator is staying in overbought zone for 14 days. View odds for this and other indicators:

  9. 2019’s best performing stocks📈: 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.

  10. 27. pro 2019.

    Major gene therapy acquisitions in 2019: Myonexus $165M 2/27 Nightstar $800M 3/4 Brammer Bio $1.7B 3/24 Paragon Bioservices $1.2B 4/15 Exonics Tx $1B 6/7 $63M 9/12 $3B 12/2 $4.8B - 12/17 (finally)

  11. 21. pro 2019.

    GeneTherapy , , , MBIO, ORTX, PRVL, , , Five companies recently acquired: how many in 2020 (by ), (by ), (by ), (pending by Roche), (pending by Astellas)

  12. 18. pro 2019.
    Odgovor korisniku/ci
  13. 16. pro 2019.
  14. credit suisse gene therapy report No Discussion is Complete Without M&A Large Pharma Has Significant Interest in GT Genetic Medicine RevolutionGene Therapy –A Subset of Genetic Medicine – Public Players

  15. 8. pro 2019.

    just a reminder: = 1/2 market cap of M&A with 7x the number of products at clinical stage = 1/6 of M&A value for AAV platform = 1/3 cap of despite having safer, more robust, gene editing

  16. 5. pro 2019.

    Alpine 4 Technologies daily chart~ looks like it's about to blow 100m AS/OS, $50m revs OTCQB $2.8m net profit Q3

  17. 3. pro 2019.

    If Astellas paid $3B for with this pipeline & still long-way to go! tells us how undervalued these days @ $8.4B with the deepest in the market, while microD & LGMD2E at late stages in human & huge manufacturing advancement & approved PMO & PPMO coming too

  18. 3. pro 2019.
    Prikaži ovu nit
  19. 3. pro 2019.

    Bold prediction (I'm prepared for the possibility this will be dead wrong): Big pharma begins divesting gene therapy assets c. 2023.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.